Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Abstract

In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)

Keywords

Affiliated Institutions

• University of Duisburg-Essen DE
• St. John's National Academy of Health Sciences IN
• Utrecht University NL
• Health Sciences Centre CA
• Carmel Medical Center IL
• Population Health Research Institute CA
• Vivantes Klinikum DE
• Boehringer Ingelheim (United States) US
• Sunnybrook Health Science Centre CA
• Hamilton Health Sciences CA
• McMaster University CA
• Lankenau Institute for Medical Research US
• Estudios Clínicos Latinoamérica AR
• Fu Wai Hospital CN

Related Publications